| Repurposing old drugs into new epigenetic inhibitors: promising candidates for cancer treatment? F Moreira-Silva, V Camilo, V Gaspar, JF Mano, R Henrique, C Jerónimo Pharmaceutics 12 (5), 410, 2020 | 38 | 2020 |
| Hydralazine and panobinostat attenuate malignant properties of prostate cancer cell lines MB Pacheco, V Camilo, N Lopes, F Moreira-Silva, MP Correia, ... Pharmaceuticals 14 (7), 670, 2021 | 19 | 2021 |
| G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models F Moreira-Silva, G Outeiro-Pinho, J Lobo, R Guimaraes, VM Gaspar, ... Biomedicine & Pharmacotherapy 150, 113031, 2022 | 13 | 2022 |
| From Therapy Resistance to targeted therapies in prostate Cancer F Moreira-Silva, R Henrique, C Jerónimo Frontiers in Oncology 12, 877379, 2022 | 11 | 2022 |
| Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness G Outeiro-Pinho, D Barros-Silva, F Moreira-Silva, J Lobo, I Carneiro, ... Translational Research 249, 110-127, 2022 | 8 | 2022 |
| EHMT2/G9a and EZH2: Epimarkers in testicular germ cell tumors H Estevão‐Pereira, C Guimarães‐Teixeira, BCT Flores, F Moreira‐Silva, ... Andrology, 2024 | 1 | 2024 |
| Novel Insights on the Role of Epigenetics in Androgen Receptor’s Expression in Prostate Cancer V Camilo, MB Pacheco, F Moreira-Silva, G Outeiro-Pinho, VM Gaspar, ... Biomolecules 13 (10), 1526, 2023 | | 2023 |
| 2D versus 3D Models: Effect of CM-272 on Prostate Cancer Cell Lines FM Silva | | 2020 |
